Lilly(US:LLY) 智通财经网·2025-11-07 07:30Core Insights - Eli Lilly's obesity drug Mounjaro has become the best-selling drug in India for October, generating sales of 1 billion rupees (approximately 11.38 million USD) [1] - The demand for Mounjaro, which has both glucose control and digestion delay effects, continues to rise in India, the world's most populous country [1] - Mounjaro's cumulative revenue reached 3.33 billion rupees by the end of October, significantly outperforming its competitor Wegovy, which had sales ten times lower in the same market [1] Financial Performance - Eli Lilly reported third-quarter sales of 17.6 billion USD, exceeding Wall Street's average expectation of 16.1 billion USD [1] - The non-GAAP earnings per share were 7.02 USD, surpassing expectations by 1.13 USD [1] - Due to the strong performance of its obesity and diabetes drugs, the company has raised its full-year guidance, indicating positive progress amid intense competition in the pharmaceutical sector [1]